Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Registro delle gravidanze Kesimpta (Ofatumumab).

9 novembre 2026 aggiornato da: Novartis Pharmaceuticals

Studio sulla sicurezza post-autorizzazione per la valutazione della gravidanza e degli esiti infantili nei pazienti trattati con Kesimpta (Ofatumumab) utilizzando il programma di sorveglianza osservazionale della gravidanza OTIS e il registro DMSKW

The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Descrizione dettagliata

The study is expected to enroll for approximately 7 years and follow the pregnant women and their infant(s) over a maximum of 21 months.

The study will be conducted as two sub-studies leveraging independent ongoing pregnancy registries:

  • The Organization of Teratology Information Specialists (OTIS) Research Group, University of California, San Diego, USA (referred to as "OTIS") will serve as data source for the Kesimpta-OTIS sub-study;
  • The German MS and pregnancy registry - Deutschsprachigen Multiple Sklerose und Kinderwunsch Register (DMSKW) at Katholisches Klinikum Bochum gGmbH, St Josef Hospital, Bochum, Germany (referred to as "DMSKW") will serve as data source for the Kesimpta- DMSKW sub-study.

Both registries will independently collect and assess data related to the pregnancy and infant outcomes of interest and provide aggregate data which will be further combined (metaanalyses) by Novartis (referred to as the Sponsor) or a designated contract research organization (CRO).

Tipo di studio

Osservativo

Iscrizione (Stimato)

725

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • California
      • La Jolla, California, Stati Uniti, 92093-0934
        • Reclutamento
        • University of California San Diego OTIS
        • Contatto:
          • Numero di telefono: 877-311-8972
        • Investigatore principale:
          • Christina Chambers

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 100 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Participants from sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively.

Descrizione

Inclusion Criteria:

Participants must meet all the criteria listed under the respective cohorts to enroll in that particular cohort of the registry:

Cohort 1: Kesimpta-Exposed Cohort

  1. Pregnant women
  2. Diagnosed with MS, with the indication validated by medical records when possible
  3. Administered Kesimpta for the treatment of MS at any time from 166 days prior to the first day of the LMP, or up to and including the end of pregnancy
  4. Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants (OTIS specific), and validated developmental performance questionnaire in live born children

Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)

  1. Pregnant women
  2. Diagnosed with MS, with the indication validated by medical records when possible
  3. May or may not have taken another medication for MS in the current pregnancy
  4. Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants (OTIS specific), and validated developmental performance questionnaire in live born children

Cohort 3: Healthy Comparison Cohort (Comparison Group 2):Kesimpta-OTIS sub-study specific

  1. Pregnant women
  2. Agree to the conditions and requirements of the study including the interview schedule, release of medical records, the dysmorphology examination of live born infants, and validated developmental performance questionnaire in live born children

Exclusion Criteria:

Women meeting any of the following criteria will be excluded from the cohort study:

Cohort 1: Kesimpta-Exposed Cohort

  1. Women who have enrolled in the Kesimpta cohort study with a previous pregnancy

  2. Women who have used Kesimpta for an indication other than a currently approved indication

  3. Women with exposure to any of the following medications within 5 half-lives (or pharmacodynamic effect when relevant) prior to conception:

    • Other anti-CD20 monoclonal antibody: same class as Kesimpta
    • S1P modulators: same class as Mayzent
    • Cladribine (Mavenclad): Based on the US label, animal studies indicate that there is positive evidence of teratogenicity for Cladribine
    • Teriflunomide (Aubagio): The teratogenecity of teriflunomide is unknown and currently under investigation.
    • New medications (marketed after 2021) indicated for the treatment of MS will be evaluated for inclusion/exclusion criteria as the study progresses.
  4. Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)

  5. Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.

Cohort 2: Disease-Matched Comparison Cohort (Comparison Group 1)

  1. Administered Kesimpta 166 days before the first day of LMP or anytime during pregnancy

  2. Women with exposure to any of the following medications within 5 half-lives (or pharmacodynamic effect when relevant) of conception:

    • Anti CD-20 monoclonal antibody
    • Cladribine (Mavenclad)
    • S1P modulators
    • Teriflunomide (Aubagio) New medications (marketed after 2021) indicated for the treatment of MS will be evaluated for inclusion/exclusion criteria as the study progresses.
  3. Women who have enrolled in the Kesimpta cohort or BAF312A2403 Mayzent cohort with a previous pregnancy

  4. Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)

  5. Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.

Cohort 3: Healthy Comparison Cohort (Comparison Group 2): Only applicable to Kesimpta-OTIS sub-study

  1. Administered Kesimpta 166 days before or Mayzent 4 days after the first day of LMP or anytime during pregnancy
  2. Women who have a diagnosis of a MS
  3. Women who have a current diagnosis of any autoimmune disease
  4. Women who have first contact with the project after prenatal diagnosis of any major structural defect
  5. Women treated with Mayzent or Kesimpta for non-MS indication
  6. Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment)
  7. Results of diagnostic test(s) that are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.
  8. Women exposed to a known human teratogenic drugs during pregnancy

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Disease-matched cohort (Comparison Group 1)

comparison group consisting of women diagnosed with MS who have not used Kesimpta during pregnancy (unexposed disease-matched comparison group).

Healthy cohort (only applicable in the Kesimpta-OTIS sub-study) (Comparison Group 2)

healthy women who are not diagnosed with MS or any other autoimmune disease, have not had exposure to a known human teratogen, and have not taken Kesimpta in pregnancy (healthy comparison group). Since the DMSKW register is an MS population specific register that does not collect data on non-MS population, this cohort is only applicable in the Kesimpta-OTIS sub-study.

Kesimpta-exposed cohort

women and infants who are exposed to Kesimpta during pregnancy to treat MS.

Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.

Altri nomi:
  • Ofatumumab

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants with major structural defects
Lasso di tempo: Up to 21 months

Number of participants with major structural defects will be collected

Up to 21 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants with spontaneous abortion/miscarriage
Lasso di tempo: Up to 21 months

Number of participants with spontaneous abortion/miscarriage will be collected

Up to 21 months
Number of stillbirth cases
Lasso di tempo: Up to 21 months

Number of stillbirth cases will be collected

Up to 21 months
Number of elective termination cases
Lasso di tempo: Up to 21 months

Number of elective termination cases will be collected

Up to 21 months
Number of preterm delivery cases
Lasso di tempo: Up to 21 months

Number of preterm delivery cases will be collected

Up to 21 months
Number of preeclampsia / eclampsia cases
Lasso di tempo: Up to 21 months

Number of preeclampsia / eclampsia cases will be collected

Up to 21 months
Number of cases with pattern of 3 or more minor structural defects
Lasso di tempo: Up to 21 months

Number of cases with pattern of 3 or more minor structural defects will be collected

Up to 21 months
Number of participants small for gestational age
Lasso di tempo: Up to 21 months

Number of participants small for gestational age will be collected

Up to 21 months
Number of participants with postnatal growth small for age at one year of age
Lasso di tempo: Up to 21 months

Number of participants with postnatal growth small for age at one year of age will be collected

Up to 21 months
Developmental performance at approximately one year of age: Michaelis developmental milestones questionnaires
Lasso di tempo: Up to 21 months

The Michaelis developmental milestones questionnaires will be used to assess the developmental performance in live born infants.

Up to 21 months
Developmental performance at approximately one year of age: Denver developmental screening test
Lasso di tempo: Up to 21 months

Denver developmental screening test will be used to assess the developmental performance in live born infants;

Up to 21 months
Number of serious or opportunistic infections in the first year of life.
Lasso di tempo: Up to 21 months

Number of serious or opportunistic infections in the first year of life will be collected

Up to 21 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 gennaio 2023

Completamento primario (Stimato)

28 febbraio 2033

Completamento dello studio (Stimato)

28 febbraio 2033

Date di iscrizione allo studio

Primo inviato

22 novembre 2022

Primo inviato che soddisfa i criteri di controllo qualità

22 novembre 2022

Primo Inserito (Effettivo)

2 dicembre 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi